Purpose: Relapse from stage 4 neuroblastoma usually carries a poor prognosis. A retrospective study using the European Bone Marrow Transplant (EBMT) Solid Tumor Registry was undertaken to define the role of megatherapy (MGT) in relapsed patients.
ROLE OF ABMT IN RELAPSE FROM NEUROBLASTOMA
of MGT, and even the need for bone marrow support. The availability of recombinant growth factors and peripheral stem-cell infusions offers the possibility of repeated courses of dose-intensive chemotherapy without prolonged myelosuppression. 42 The only randomized trial to compare myeloablative MGT versus no further therapy, the European Neuroblast Study Group (ENSG) 1 study, showed an advantage for MGT on progression-free survival (PFS) and survival. However, the study was small, with a 30% refusal rate, and needs confirmation.
2 " Berthold et a12 4 performed a matched-pair analysis within the German Pediatric Oncology Society (GPO)-NB85 study to compare transplanted patients with those on conventional chemotherapy, but found no advantage for transplant patients. The analysis reported by Shuster et al 43 compared two Pediatric Oncology Group (POG) studies and also suggested no benefit for patients in complete remission (CR) or partial remission (PR) from intensification with MGT and bone marrow transplantation (BMT). Thus, the impact of myeloablative MGT and bone marrow rescue on survival, especially for patients in first CR (CR1), achieved with modern induction treatments with escalated dose-intensity is matter of controversy and several investigators have emphasized the need for reevaluation in a randomized trial. Relapse occurs most frequently during the first 2 years,41,44,45 but is observed up to 5 years, and there are still some patients reported to relapse beyond this period.46 Long-term survival rates for children undergoing both induction and consolidation with or without bone marrow rescue are thus only 20% at 5 years and 15% at 6 to 7 years. Relapse from stage 4 neuroblastoma, reflecting the failure of previous therapeutic regimens, is hence a major issue for pediatric oncologists.
In the past, rather few relapse patients were entered onto prospective protocols. 47 Reinduction treatments were usually adapted to previous treatment schedules, a procedure which favors previously unused agents, and the majority of patients were treated by a cascade of treatment modalities in various phase II studies. Response data from chemotherapy dose-escalation studies 14 ,16, 47 indicate that mlBG48-5 0 and anti-GD251-53 appear promising, whereas treatments with interleukin-2 have shown marked toxicities and disappointing response rates. 54 ' 55 Another approach is the use of differentiating agents, such as retinoic acid. 5 6 ' 57 However, no conclusions can be drawn from these data as to which approach is superior to prolong survival after relapse, especially if associated toxicities are taken into consideration. Thus, there are strong arguments to treat relapse patients more homogeneously within a cooperative prospective study.
Using the European Bone Marrow Transplant (EBMT) Solid Tumor Registry data with more than 600 transplanted neuroblastoma patients, it is the aim of this report to investigate the role of MGT followed by autologous or allogeneic bone marrow rescue in relapsed patients. The results could provide information regarding the role of MGT in patients randomized not to receive elective consolidation in a future randomized study.
PATIENTS AND METHODS

Patients
The subjects of this retrospective analysis are 33 boys and 15 girls older than 1 year of age at diagnosis who relapsed from stage 4 neuroblastoma. They were reported to the EBMT Solid Tumor Registry by 11 cancer centers in five European countries between April 1983 and July 1991. Median age at diagnosis was 47 months (range, 14 to 134) and at relapse 62 months (range, 21 to 201). Before the event of relapse, all of these patients had achieved a CRI during primary treatments. The median follow-up time is 95 months (range, 25 to 185) since diagnosis. Two groups of patients were distinguished. Group A includes 30 patients who received only conventional-dose primary treatments, whereas 18 group B patients had initial treatment intensification by MGT. Patients characteristics, including sex, age, sites of disease at diagnosis, primary treatments, time to relapse, type of relapse, and treatments at relapse, are listed in Tables 1 and 2 .
Definition of Disease Status
Assessment of disease status included primary tumors, urinary catecholamine excretions, bone lesions, and bone marrows, as well as other distant metastases. Patients' evaluations at diagnosis and relapse were heterogeneous, since patients were treated on various national protocols over a 13-year period. Primary tumors and relapse sites were evaluated with computed tomographic (CT) scans in the majority and with additional ultrasound in some. Evaluation of bone disease was performed with technetium-99 scans or mIBG scans or both, and some of the patients received x-rays in addition. Bone marrow aspirates were performed on one to 10 different sites; the number of core biopsies ranged from one to four.
CR at the end of primary treatment was documented by standard diagnostic means. This included reevaluation of the bone marrow by aspirates (or biopsies) and exclusion of residual bone disease by " 99 Tc scans and/or mIBG. Residual disease at the primary site was usually evaluated by ultrasound and/or CT scans.
Amplification of N-myc oncogene and lactic dehydrogenase and ferritin levels were not routinely evaluated in these patients and are not available for analysis.
Primary Treatments
Treatment protocols for group A and B patients are listed in Table  3 . The majority of these multiagent chemotherapies have been previously published and included the following: CADO, 8 Abbreviations: DX, diagnosis; F, female; M, male; A, nodes below diaphragm; B, bone marrow; D, mediastinum; E, Hutchinson's syndrome; Mm, mucous membrane; N, nodes above diaphragm; 0, skeleton; P, lungs; V, liver; W, adrenal; X, other site; Z, retroperitoneum; C, chemotherapy; R, radiotherapy; S, surgery; T, immunotherapy; nr, not reported; CR2/PR2, sensitive relapse; RR/UR, resistant or untreated relapse; NA, not assessable; PD, progressive disease; SD, stable disease; ADF, alive disease-free; DOD, dead of disease; LTFU, lost to follow-up; MTD, MGT-related toxic death.
in terms of survival. Treatment modalities in group A and B were
Only two patients of the total cohort experienced relapse at the not significantly different: 17% and 6% had multiagent chemotherapy primary tumor site, ie, retroperitoneal. Disseminated relapses most only, the majority had additional surgery (63% and 83%, respectively), frequently involved the bone marrow (65%), followed by bones and, finally, 20% and 11% had surgery and radiotherapy. The major (47%), retroperitoneal sites (18%), and distant lymph nodes (16%). difference in intensity of primary treatment is the additional MGT/ Hutchinson's syndrome was present in only 6% of the cases at BMT in the 18 group B patients. Six patients received TBI plus melrelapse, and liver, lungs, and skin were rare relapse sites observed phalan (L-PAM), with VCR in addition in five. MGT without TBI in a total of only 8% of cases. Sites of recurrent disease were thus was used in the other 12 patients and was L-PAM-based in 11. Two predominantly bone marrow and bones, but otherwise appear to received L-PAM only, one L-PAM and VM26, and eight L-PAM, parallel the disease pattern observed at diagnosis. In group B, carmustine (BCNU), and VM26. One patient received a combination significantly more patients showed bone metastases at relapse (13 of BCNU, VM26, and CBDCA. of 19; 68%) than in group A (10 of 30; 33%). Otherwise, there was Reinduction regimens after relapse included CDDP, CBDCA, VPI6, VM26, CYC, VCR, DXR, and peptichemio (PTC). Of note, the combination of VP 16-CDDP or VPI 6-CBDCA was used in the majority of patients. 4 '16 2 0
Time to Relapse and Frequencies ofRelapse Sites
Response to Relapse Treatments
Thirty-four patients (group A and B) were sensitive to reinduction chemotherapy. The reinduction response rate in group A was 73%, with 14 patients in CR (63.5%) and eight in PR. In group B, the response rate was 67%, with two patients in CR (16.7%) and 10 in PR. In group A, two of 30 patients (6.7%) were resistant to reinduction treatments and a further six of 30 (20%) directly underwent MGT. In group B, two of 18 patients (11%) were resistant to reinduction treatments and four of 18 (22%) directly underwent MGT.
Bone Marrow Harvesting and Purging
Autologous bone marrow was used in 42 patients. Six patients received allogeneic bone marrows. Autologous bone marrows were treated in vitro in 32 patients using either monoclonal antibodies and immunomagnetic beads as previously described in detail (n = 11)58-60 or by 4 hydroperoxycyclophosphamide (n = 2 1). 61 Thirteen autologous marrows were positive at harvest, but only eight of these were purged.
MGT Regimens
MGT regimens used at relapse (MGTR) are listed in Table 4 . Supportive care was performed in all the centers as standard for patients undergoing prolonged severe bone marrow aplasia.
Statistical Methods
Sex, interval from diagnosis to relapse, response to relapse treatments, and influence of initial treatment intensity were analyzed.
Probability of survival was analyzed according to the Kaplan-Meier method.62 Actuarial survival curves were compared using the logrank test. 
RESULTS
Response to Reinduction, MGTR, and Survival
Response behavior and time of survival duration after MGTR are listed in Tables 5 and 6 for both groups. Fourteen patients in group A had already achieved a second CR (CR2) with reinduction treatments. Thus, 16 group A patients still had measurable disease when they underwent MGTR. This group showed a response rate to MGTR of 62.5% (10 of 16 patients) and a CR rate of 50% (eight of 16 patients). Thus, 22 of 30 patients achieved CR2 with reinduction and/or MGTR. Three of 30 (two had achieved a CR before MGTR and one after MGTR) are alive in CR2 22, 46, and 47 months since MGTR. Thus, a longer duration of CR2 than of CR1 is observed in these patients who are still alive. One CR2 patient who achieved this response status after MGTR was lost to follow-up at 8 months. A further CR2 patient (who had achieved CR2 before MGTR) experienced another relapse, but reached a third CR and is alive 109 months since MGTR. Of note, all six patients who received double MGTR are part of group A. 
Abbreviations: N-mustard, mechlorethamine; IFO, ifosfamide; PTC, peptichemio; IFN, interferon; ARAC, cytarabine; S, additional surgery; S + R, additional surgery and radiotherapy.
In group B, two patients achieved CR2 with reinduction and 16 patients had measurable disease. The response rate to MGTR (eight of 16 patients) was 50% and the CR rate 19%. In this group, only one of 18 patients is alive with disease 36 months since MGTR. 
Engraftments
Causes of Death
Group A. Four patients died of MGTR-related toxicity. The toxic death rate was thus 13%. Two CR2 patients died within the first 100 transplant days, one with interstitial pneumonitis at day 23 and the other of sudden death of unknown cause at day 25. One further patient had achieved CR with MGTR but died with interstitial pneumonitis and multiple organ failure on day 141. One untreated relapse patient died with multiple organ failure at day 9. The other patients died with progressive disease between 2 to 92 months after MGTR.
Group B. Four patients experienced major MGTRrelated toxicity. All of these patients died within the first 100 transplant days for a toxic death rate of 27%. One patient was in CR2 before MGTR and died on day 32 with fungal infection. The other had achieved CR2 with MGTR, but died at day 33 (with undocumented infection involving the CNS and lungs). One patient in second PR (PR2) died of septicemia on day 5 and one untreated relapse died of liver failure on day 23.
Actuarial Overall Survival According to Univariate Risk Factor Analysis
The actuarial overall survival for the 48 relapse patients is 20% at 5 years with a median survival after diagnosis of 34 months (Fig 1) . Results of the univariate analysis of factors tested for their influence on survival at 3 and 5 years after diagnosis are listed in Table 7 . Univariate analysis identified the following significant adverse prognostic factors.
Early relapse within 12 months from diagnosis was an indicator of poor prognosis (P < .0001). Early relapses were equally distributed in group A (12 of 30) and in group B (eight of 18), 40% and 44%, respectively.
Influence of pretreatment intensity showed a significantly worse prognosis for group B patients (P = .019). Eighteen patients with previous MGT (group B) were identified as a subgroup with especially poor outcome, with only one patient still alive with disease beyond 1 year. In contrast, patients treated with conventional-dose chemotherapy only during primary treatments had a sig- nificantly better survival rate, although no plateau has been reached (Fig 2) .
Response to relapse treatments was equally a highly significant factor. Patients resistant to reinduction treatments or undergoing MGT immediately fared worse than their chemosensitive counterparts (P = .0001). Considering sensitive relapses only, there was still a significant difference between group A and group B. For group A patients, sensitive relapses (CR2/PR2) in comparison to resistant or untreated relapses again had a significantly better outcome. No such difference is seen in group B patients due to their generally poor outlook.
Single grafts did worse than double grafts, although the latter refers to only six patients (P = .024).
In contrast, no influence was observed concerning sex, bone, or bone marrow involvement before MGTR. Furthermore, no significant difference in actuarial survival rates was observed comparing stage 4 neuroblastoma patients on the EBMT registry over 1 year of age consolidated with myeloablative MGT in CR1 with those patients in CR2 treated with MGTR for the first time at relapse. In fact, the actuarial survival rate is 25% at 90 months since diagnosis and 27% at 60 months' post-MGT for CRI patients; in CR2 patients, the rate is also 25% at 90 months since diagnosis and 17% at 60 months' post-MGTR (Figs 3 and 4) .
Multivariate Analysis
All clinical factors of potential predictive value were included in the multivariate analysis. Three adverse prognosis factors were confirmed by multivariate analysis: interval less than 12 months between diagnosis and relapse (P < .0001; relative risk = 7.91), nonresponding or untreated relapse (P = .0002, relative risk = 3.42), and previous MGT during primary treatments (P = .055; relative risk = 2.40).
DISCUSSION
This report confirms that CR as the ultimate goal of primary treatments may not mean cure. In fact, patients continue to be at risk of disease recurrence irrespective of the duration of the first remission. 46 In most cases, the recrudescence of tumor leads to death of disseminated disease within a short period of time. However, the definition of CR status is highly dependent on the quantity and quality of methods involved to exclude minimal residual disease. A consensus on inter-
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,, national staging criteria 66 was reported in 1988, whereas our report encompasses a much wider time period, so initial staging and confirmation of remission status has not been homogeneous over the years. Nevertheless, apart from staging quality a further question is to what degree a patient can overcome minimal residual disease without further treatment either with help of his own immune system (stimulated or unstimulated) or due to maturation and differentiation of residual neuroblastoma cells. In this report, a retrospective analysis was performed on relapsed patients who presented with a diagnosis of disseminated disease at age older than 12 months. All of these patients relapsed after a documented CR1. Patients who failed to respond early or never achieved CR do not appear in this analysis and results thus refer to a selected group of patients. However, it was the aim of this analysis to study the potential influence of myeloablative MGT on prognosis in such patients. Potential bias of observations and conclusions is inherent to any retrospective review; thus, interpretation warrants caution, but the results could kindle interest in prospective evaluation.
It has previously been reported for acute lymphoblastic leukemia in childhood67-70 that recurrent disease either on therapy or within the first 6 months after treatment stops indicate very poor outcome. To our knowledge, this is the first time that time to relapse of less than 12 months from diagnosis is reported for neuroblastoma as a significant factor influencing outcome.
Degree of response to reinduction therapy at relapse is also an important prognostic indicator. Response behavior is most likely related to the extent of resistant tumor-cell clones developed during previous treatments, and this phenomen appears to be induced in a higher degree in patients already treated by MGT. Thus, there is no indication for MGT in patients who are resistant to reinduction. Further, it cannot be recommended to submit Group A, n = 30, P = .12; (---),group B, n = 18, P = .06; P = .05.
patients directly to MGT, ie, without reinduction, since this group had an adverse outcome as observed for the resistant-relapse patients. Considering cost and toxicity of MGT followed by bone marrow rescues, these patients should undergo different innovative treatment approaches, ie, mIBG treatment, which has been reported to result in CR even in patients who appear to be chemoresistant.
In contrast, patients who are sensitive to chemotherapy, especially those without previous MGT, appear to be good candidates. The response rates in patients with measurable disease appear promising and in favor of a dose-response relationship, although the duration of the progression-free interval is short.
A further important observation of this analysis is the influence of treatment intensity during primary treatments. Patients already treated with MGT before the event of relapse appear to present a very poor prognosis group. Only one of 18 patients is still alive with disease beyond 1 year after MGTR. In addition, this group showed a higher MGTR-related toxicity rate. A possible explanation is that increased treatment intensity during primary treatment including prior MGT compromises the quality of the marrow used for MGTR salvage and probably also damages the marrow stroma. Consequently, it appears from these data that patients with previous MGT do not benefit from a second procedure and thus should be entered onto innovative phase II studies.
Patients in CR2 without prior MGT are a particularly interesting group. Thus, we compared survival of these CR2 patients with the actuarial survival of EBMT registry patients intensified with myeloablative MGT in CR1. In fact, actuarial survival rates at 90 months after diagnosis in both groups appear to be equivalent, reaching approximately 25%. However, the CR2 group is small and it is months from diagnosis an open question as to how many relapse patients will achieve CR2, since this was never evaluated in a prospective manner in a controlled study. Nevertheless, this observation could kindle interest to evaluate whether myeloablative MGT can be postponed after the event of relapse for a group of selected good-risk patients. Such a strategy would take into account further front-line doseescalation without bone marrow rescue as used in some most recent induction regimens, and also the acute transplant-related mortality rate of up to 20% in CR I patients as recently reported. 32 , 33 Thus, in this selected group of patients, it could be justified to reevaluate the influence of myeloablative MGT on prognosis in a randomized trial. 4 RELAPSE FROM NEUROBLASTOMA STAGE 4 patients using aggressive surgery, local irradiation, and MGT/autologous BMT. The data appear promising, since 10 of 28 patients were still alive 9 to 90 months posttransplant. However, no details were given on patient age, number of relapse patients, type of relapse, and disease status before consolidation with MGT/autologous BMT. Thus, the better outcome in their series could have been influenced by several factors. It also appears that fewer patients had disseminated disease on entry to their program in comparison to the EBMT registry patients, where only two patients had local relapses and all were stage 4 and older than 1 year. On the other hand, it appears that aggressive local treatment to the various disease sites by surgery and/or irradiation before MGT/ BMT could have contributed. These treatment modalities were used to a much lesser degree in the EBMT registry patients.
ROLE OF ABMT IN
In summary, since response to reinduction and previous MGT are independent prognostic variables in multivariate analyses, we suggest that these factors should be taken into consideration when planning relapse treatment schedules in the future. A standard intensive reinduction treatment could select those patients who are still sensitive to chemotherapy to be treated by MGT and bone marrow rescue. Patients who show resistant relapse or who have been treated previously by MGT appear to be unsuitable candidates for such a procedure.
